A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

NCT06653842 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Cutaneous Venous Malformations

Interventions

DRUG: QTORIN 3.9% rapamycin anhydrous gel

Sponsor

Palvella Therapeutics, Inc.